Erratum: Epidermal Growth Factor Receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer (Clinical Cancer Research(2004)10(8594–602)Doi:10.1158/1078-0432.CCR-04-0690)

Bradley A. Schiff, Andrea B. McMurphy, Samar A. Jasser, Maher N. Youne, Dao Doan, Orhan G. Yigitbasi, Seungwon Kim, Ge Zhou, Mahitosh Mandal, Benjamin N. Bekele, FChristopher C. Holsinger, Steven I. Sherman, Sai Ching Yeung, Adel K. El-Naggar, Jeffrey N. Myers

Research output: Contribution to journalComment/debatepeer-review

Fingerprint Dive into the research topics of 'Erratum: Epidermal Growth Factor Receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer (Clinical Cancer Research(2004)10(8594–602)Doi:10.1158/1078-0432.CCR-04-0690)'. Together they form a unique fingerprint.

Medicine & Life Sciences